QHSLab Inc Stock Price, News & Analysis

USA Equities Corp. (OTCQB: USAQ) has launched AllergiQT™ - Quick Test, an FDA-cleared skin test designed for primary care settings to identify environmental and food allergens. This product targets independent primary care physicians, streamlining allergy testing and treatment, which is essential as the number of allergists declines. With around 60 million Americans affected by allergic disorders, AllergiQT™ presents a significant market opportunity. The company expects to expand its product portfolio to address major chronic illnesses.

USA Equities Corp. (OTCQB: USAQ) reported a significant increase in revenue, surpassing $1 million for the first nine months of 2021, compared to zero in the same period of 2020. The gross margin improved to 46% year-to-date and reached 48% in Q3. Notably, the company reduced its debt by converting $50,000 of a promissory note into 76,923 shares of stock. CEO Troy Grogan highlighted growth driven by digital platforms and allergy diagnostics, despite challenges from the COVID-19 pandemic affecting sales. The company anticipates regaining sales momentum as medical staffing improves.

USA Equities Corp. (OTCQB: USAQ) has enhanced its investor outreach by adding a comprehensive presentation outlining its growth strategy, key achievements, and product offerings. The company targets over 250,000 independent U.S. primary care physicians and capitalizes on the rising acceptance of digital medicine post-COVID-19. Following a successful capital raise of $750,000, USAQ aims to accelerate its growth in the medical practitioner market. With a current share price of $0.78 and a low market cap of $6.8 million, Litchfield Hills Research assigned a 'Buy' rating, projecting a target price of $5.

AUSTIN, TX / ACCESSWIRE / September 9, 2021 / SmallCapVoice.com Inc. released an interview with Troy Grogan, CEO of USA Equities Corp. (OTCQB: USAQ), highlighting the Company’s Q2 financial results. Revenue surged over 50% from Q1, with the Company also raising $750,000 in growth capital to enhance its digital medicine and testing services. Grogan discussed expanding the customer base through investments in sales and marketing and the development of new products like digital therapeutic monitoring tools, aimed at addressing rising allergy cases and improving chronic care.

USA Equities Corp. (USAQ) reported second quarter 2021 results, showing revenue of $455,622, a 50% increase from Q1 2021. They successfully raised $750,000 to expand their digital medicine applications and customer base. The acquisition of AllergiEnd® assets enhances their business strategy, tapping into a market with over 60 million allergy sufferers in the U.S. They reported a gross margin of 45.5%, and plan to leverage new partnerships to bolster their sales and marketing efforts. A recent study published highlights the benefits of their allergy management solutions.

USA Equities Corp (OTCQB: USAQ) has published a research paper on Consultant360, highlighting its Allergy Management Evaluation (AME) tool designed to assist clinicians in identifying and managing allergies. The AME tool enhances patient care by enabling digital health assessments, allowing for effective remote monitoring while reducing in-person visits. Positive clinician feedback indicates the tool improves workflow efficiency. The company aligns its business model with the increasing acceptance of digital medicine, encouraged by new reimbursement codes from Medicare for remote therapeutic management.

USA Equities Corp. (OTCQB: USAQ) reported strong financial growth for Q2 2021, achieving a 49.9% revenue increase to approximately $456,219 compared to Q1 2021. The gross profit grew 55.5% sequentially, resulting in a gross margin of 45.5%. The company also strengthened its financial position with cash reserves of $145,947, a 54.7% increase from year-end 2020. CEO Troy Grogan highlighted the success of allergy diagnostic kits and strategic partnerships aimed at expanding market reach.

USA Equities Corp. (OTCQB: USAQ) has entered a distribution agreement with a physician management services organization (MSO) to distribute its AllergiEnd® allergy diagnostic and immunotherapy solutions. This collaboration aims to enhance the practice network of independent medical providers and optimize marketing support, facilitating structured rollout to ensure effective training. CEO Troy Grogan highlighted the deal as a strategic move to broaden client base and revenue streams. With a robust national physician footprint, USAQ is positioned for growth in the latter half of fiscal 2021.

USA Equities Corp. (OTCQB: USAQ) has acquired the AllergiEnd® method patent, trademark, and website from MedScience Research Group, Inc. This acquisition aims to enhance USAQ's value-based healthcare solutions and align its offerings with growing market demands. AllergiEnd® products, which are FDA-cleared, enable primary care providers to diagnose and treat allergies, addressing the needs of around 60 million Americans suffering from allergic disorders. The move is expected to improve USAQ's revenue opportunities and integrate AllergiEnd® into its existing platforms.